Peanut‐induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry

Maris, Ioana; Dölle‐Bierke, Sabine; Renaudin, Jean‐Marie; Lange, Lars; Koehli, Alice; Spindler, Thomas; Hourihane, Jonathan; Scherer, Kathrin; Nemat, Katja; Kemen, Christoph; Neustädter, Irena; Vogelberg, Christian; Reese, Thomas J.; Yıldız, İsmail; Szépfalusi, Zsolt; Ott, Hagen; Straube, Helen; Papadopoulos, Nikolaos G.; Hämmerling, Susanne; Staden, Ute; Polz, M.; Mustakov, Tihomir B.; Cichocka‐Jarosz, Ewa; Cocco, Renata Rodrigues; Fiocchi, Alessandro; Fernández‐Rivas, Montserrat; Worm, Margitta

doi:10.1111/all.14683

Cited by 41 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, laboratory tests can help physicians evaluate anaphylaxis phenotypes and find causative agents. As shown in Table 3 [ 25 , 26 , 62 - 66 ], inflammatory mediators (histamine, tryptase, chymase, carboxypeptidase A3, and platelet-activating factor) are measured during the acute phase and/or stable condition (at least 24 hours after all signs and symptoms have been resolved) to confirm the diagnosis of anaphylaxis [ 67 ]. Meanwhile, the basophil activation test, serum-specific IgE measurement, and skin tests as well as component-resolved diagnostics are used to find causative agents.…”

Section: Diagnosismentioning

confidence: 99%

“…For drug desensitization, administration of drugs (with increasing doses) can achieve a tolerant state to targeted drug doses [ 83 ]. Desensitizations can be successful for patients with anaphylaxis induced by chemotherapy, biologics, NSAIDs, and antibiotics [ 26 ].…”

Section: Chronic Managementmentioning

confidence: 99%

“…Anaphylaxis belongs to type I hypersensitivity reaction, where mast cells and basophils are key effector cells to release mediators [ 23 ]. Recently, contributions of T cells, macrophages, and monocytes have been reported in cases induced by chemotherapy and monoclonal antibodies [ 25 , 26 ]. Therefore, a new classification of anaphylaxis phenotypes is based on type I, cytokine storm like, and mixed reactions [ 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

“…Recently, contributions of T cells, macrophages, and monocytes have been reported in cases induced by chemotherapy and monoclonal antibodies [ 25 , 26 ]. Therefore, a new classification of anaphylaxis phenotypes is based on type I, cytokine storm like, and mixed reactions [ 25 , 26 ]. Various phenotypes from different pathomechanisms made anaphylaxis difficult to diagnose and treat.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recent update on the management of anaphylaxis

et al. 2021

View full text Add to dashboard Cite

Anaphylaxis is a life-threatening systemic allergic reaction presenting various clinical manifestations. Its prevalence has increased in almost all age groups and both sexes. Food, venom, and drugs are major causes in both children and adults; a higher prevalence of food-induced anaphylaxis is noted in children, while a higher prevalence of drug-induced anaphylaxis is noted in adults. The pathogenic mechanism is mediated by immunologic and nonimmunologic mechanisms, where mast cells and basophils are key cells that release mediators. A diagnosis of anaphylaxis is mainly based on clinical symptoms and physical findings; however, an increased serum tryptase level is a useful biomarker. Epinephrine is the first-line drug to treat acute symptoms, and an epinephrine auto-injector should be prescribed for each patient. Antihistamines and systemic corticosteroids are used to relieve symptoms. This review updates current issues in the management of anaphylaxis as well as the new guidelines for proper diagnosis and treatment.

show abstract

Section: Diagnosismentioning

confidence: 99%

Section: Chronic Managementmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recent update on the management of anaphylaxis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…While allergies to food allergens, such as cow's milk and hen's egg, show a strong to moderate tendency to develop tolerance in childhood, peanut allergy is often known to persist into adulthood [5][6][7]. Recent analyses of clinical profiles of peanut allergy patients show that anaphylactic reactions due to peanut allergy are more likely to be particularly severe and result in hospitalization [8]. The peanut allergens clinically relevant for severe reactions are heat-stable and belong to the family of storage proteins.…”

Section: Introductionmentioning

confidence: 99%

Current developments in the treatment of peanut allergy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Peanut allergy is a potentially life-threatening disease because it leads to severe allergic reactions, especially in children but also in adults. So far, allergen avoidance is the most effective therapy for treating peanut allergy. In this article, current developments of peanut allergy specific immunotherapy are critically discussed based on the existing literature. These include sublingual, epicutaneous and oral peanut immunotherapy. Nonspecific treatment approaches with new-targeted antibodies such as anti-IgE (omalizumab) or anti-IL-4/IL-13 receptor antibodies (dupilumab) can also be used to treat peanut allergy with regard to the mode of action of these antibodies. Multiple studies are already available for omalizumab and are currently performed with dupilumab. Whether and which therapies for the treatment of peanut allergy will be available on the market in the future is not only relevant in terms of clinical effectiveness in the sense of a long-term stable increase in the threshold level, but also in terms of the tolerability in everyday life of affected patients.

show abstract

Beliefs about food allergies in adolescents aged 11–19 years: A systematic review

Newman

Chater

Knibb

2022

Clinical & Translational All

View full text Add to dashboard Cite

Aims Research suggests of people with food allergy (FA), adolescents have the highest risk of fatal allergic reactions to food, yet understanding of this population and how they manage their condition is limited. Understanding beliefs and how they affect behaviour could inform ways to reduce risk taking behaviour and fatal reactions in adolescents. This systematic review aimed to explore beliefs adolescents hold about their FA, and how these may be associated with FA management. Demographics Adolescents aged 11–19 years with FA. Methodology A systematic search of seven databases was conducted. Papers of any design were included that reported on the beliefs about FA in adolescents aged 11–19 years. Data was systemised by narrative thematic analysis. Findings 20 studies were included. Themes included navigating FA in different environments, carriage and use of adrenaline auto‐injectors, management of the risk of anaphylaxis, behaviour and understanding of others, and food‐allergic identity. Implications Adolescents with FA hold a variety of condition beliefs; some beliefs were related to behaviour that could lead to an allergic reaction, while other beliefs were related to protective behaviours. Further research into understanding adolescent beliefs in order to inform clinical management and reduce the risk of potential fatal reactions is essential.

show abstract

Peanut‐induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 41 publications

References 31 publications

Recent update on the management of anaphylaxis

Recent update on the management of anaphylaxis

Current developments in the treatment of peanut allergy

Beliefs about food allergies in adolescents aged 11–19 years: A systematic review

Contact Info

Product

Resources

About